Sweden's RaySearch Q1 net sales fall 12% on strong krona, order timing

RaySearch Laboratories AB (publ)

29/04/2026 06:42

Overview

Sweden medical software firm's Q1 net sales fell 12% yr/yr, organic growth -5%

Adjusted EPS and net income declined from prior year

Company cites strong krona, tough comparison, and order timing for lower sales

Outlook

RaySearch maintains operating margin target of at least 25% for full yr 2026

Company sets new operating margin target of at least 30% for full yr 2028

Company expects demand for integrated cancer care workflows to remain strong

Result Drivers

CURRENCY IMPACT - Co said a stronger Swedish krona had a significant negative effect on results

COMPARISON EFFECT - Co said prior year included a larger order from China, making for a tough comparison

ORDER TIMING - Co noted revenues may vary on a quarterly basis due to timing of orders

Company press release: ID:nMFN3ZtVtc

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
SEK 290 mln
Q1 Adjusted EPS
SEK 1.55
Q1 Net Income
SEK 53 mln
Q1 Operating Profit
SEK 68 mln
Q1 Order Backlog
SEK 1.62 bln
Q1 Orders
SEK 356 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for RaySearch Laboratories AB (publ) is SEK290.00, about 39.2% above its April 28 closing price of SEK208.40

The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 26 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)